Increasing Diversity in Clinical Trials
Researchers share approaches for improving participation among underrepresented groups at AACR conference.
Progress Against Cancer
Researchers share approaches for improving participation among underrepresented groups at AACR conference.
As the number of targeted cancer therapeutics has increased, the percentage of tumors carrying molecular alterations eligible for treatment by those drugs nearly doubled from 2017 to 2022. Precise, biomarker-guided therapies made up almost...
The AACR Annual Meeting 2023, held April 14-19, commemorated several milestones, including the 25th anniversary of the approval of the blockbuster breast cancer drug trastuzumab (Herceptin). Coincidentally, Lisa Coussens, PhD, MD (hc), FAACR, FAIO,...
by Ashok Venkitaraman, MBBS, PhD Singapore will hold its 15th Frontiers in Cancer Science (FCS) conference November 6-8 at the University Cultural Centre, National University of Singapore (NUS). This annual conference started in 2009...
The FDA has approved pembrolizumab for the treatment of certain surgically removable tumors before and after resection. The U.S. Food and Drug Administration (FDA) has approved the immunotherapy pembrolizumab (Keytruda) for use in combination...
The FDA approved nivolumab for some patients with melanoma whose tumor was completely removed through surgery and has not spread. The U.S. Food and Drug Administration (FDA) has approved the checkpoint inhibitor nivolumab (Opdivo)...
Rising prevalence of non-melanoma skin cancer leads to more deaths across the globe and other highlights from this week in cancer news, selected by the editors of Cancer Today.
AACR is a pioneer in the study of racial/ethnic and other disparities in cancer research and care. The 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically...
The FDA approved encorafenib with binimetinib as a treatment for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration has approved encorafenib (Braftovi) with binimetinib (Mektovi) to treat adult patients...
Minority groups less likely to receive palliative care, and radiation oncology meeting focuses on shorter radiation courses.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More